Centessa Pharmaceuticals plc and Javad Shahidi, M.D., M.Sc., Chief Medical Officer, mutually agreed that Dr. Shahidi will be departing from the Company. Dr. Shahidi's last day with the Company will be October 14, 2022. Dr. Shahidi's departure was not the result of any disagreement regarding any matter relating to the Company's operations, policies or practices.

The Company thanks Dr. Shahidi for his contributions. Antoine Yver, M.D., M.Sc., Chairman of Development of the Company, will assume all responsibilities currently held by Dr. Shahidi effective October 14, 2022. Dr. Yver assumes these responsibilities with over 30 years of extensive global drug development and global program leadership experience in oncology and rare diseases, including deep expertise in regulatory affairs and policy.

Dr. Yver has led the approvals for 11 different drugs, including Tagrisso, Lynparza, and Enhertu. Prior to joining Centessa in 2021, Dr. Yver was Executive Vice President and Global Head, R&D Oncology, and Chair of the Cancer Enterprise at Daiichi Sankyo Company Ltd. Previously, Dr. Yver was with AstraZeneca, PLC, most recently serving as Senior Vice President, Global Medicine Head, Oncology, and Global Medicines Development China Lead. Dr. Yver currently serves as an independent director on the Board of Sanofi and Spotlight Therapeutics.